Agios Pharmaceuticals
AGIO
198 hedge funds and large institutions have $4.49B invested in Agios Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 42 funds opening new positions, 83 increasing their positions, 47 reducing their positions, and 20 closing their positions.
400% more funds holding in top 10
Funds holding in top 10: 1 → 5 (+4)
110% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 20
77% more repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 47
67% more capital invested
Capital invested by funds: $2.69B → $4.49B (+$1.81B)
11% more funds holding
Funds holding: 178 → 198 (+20)
0.59% less ownership
Funds ownership: 96.38% → 95.79% (-0.59%)
5% less call options, than puts
Call options by funds: $24M | Put options by funds: $25.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$101M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$99.7M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$73.2M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$54M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$52.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$35.6M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$34.5M |
| 3 |
Capital World Investors
Los Angeles,
California
|
-$18.8M |
| 4 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
-$14.3M |
| 5 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$13M |
AGIO Hedge Fund Activity: Q1 2018 in Review
198 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q1 2018, worth a combined $4.49B — up 67% from $2.69B a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new AGIO positions and 20 closed out — a net gain of 22 holders — while 83 added to existing stakes and 47 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $101M. The largest seller was Janus Henderson Group, cutting an estimated $35.6M.
- 198 institutional investors held Agios Pharmaceuticals (AGIO) as of Q1 2018, up from 178 in Q4 2017.
- Funds reported $4.49B of Agios Pharmaceuticals stock for Q1 2018, up 67% quarter-over-quarter.
- 42 funds opened new Agios Pharmaceuticals positions in Q1 2018 and 20 closed out, a net change of +22 holders.
- The largest Agios Pharmaceuticals buyer in Q1 2018 was T. Rowe Price Associates, an estimated $101M added.
- The largest Agios Pharmaceuticals seller in Q1 2018 was Janus Henderson Group, an estimated $35.6M sold.
Based on aggregated 13F filings for Q1 2018.